Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus as Adjunctive Treatment for Focal Refractory Epilepsy
NCT07095933Phase 1Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in epilepsy, sponsored by Xuanwu Hospital. Primary endpoint: Percent Change From Baseline in Seizure Frequency Per 28 Days at 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
everolimus
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT07095933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095933.